{"id":53055,"date":"2026-01-06T13:56:36","date_gmt":"2026-01-06T05:56:36","guid":{"rendered":"https:\/\/flcube.com\/?p=53055"},"modified":"2026-01-06T13:56:36","modified_gmt":"2026-01-06T05:56:36","slug":"genhouse-bios-mat2a-inhibitor-gh31-wins-nmpa-and-fda-clinical-trial-approvals","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53055","title":{"rendered":"Genhouse Bio&#8217;s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals"},"content":{"rendered":"\n<p><strong>Genhouse Bio (Suzhou) Co., Ltd.<\/strong> (invested in and incubated by Viva Biotech) announced that <strong>China&#8217;s National Medical Products Administration (NMPA)<\/strong> approved the clinical trial application for <strong>GH31<\/strong>, a <strong>Category\u202f1 MAT2A inhibitor<\/strong>, just <strong>10 days after FDA approval<\/strong>. GH31 targets <strong>MTAP\u2011deleted tumors<\/strong> through a <strong>synthetic lethality mechanism<\/strong>, representing a <strong>first\u2011in\u2011class<\/strong> opportunity in <strong>solid tumor therapy<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>GH31 tablets<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Genhouse Bio (Suzhou) Co., Ltd. (Viva Biotech portfolio)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>MAT2A inhibitor (methionine adenosyltransferase 2A)<\/td><\/tr><tr><td><strong>FDA Approval<\/strong><\/td><td>Clinical trial application approved <strong>25\u202fDec\u202f2025<\/strong><\/td><\/tr><tr><td><strong>NMPA Approval<\/strong><\/td><td>Clinical trial application approved <strong>04\u202fJan\u202f2026<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors with MTAP deletion<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category\u202f1 innovative drug<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td><strong>First\u2011in\u2011class MAT2A inhibitor<\/strong> globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-synthetic-lethality\">Mechanism of Action: Synthetic Lethality<\/h2>\n\n\n\n<p><strong>Target Biology<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MAT2A<\/strong>: Key enzyme in methionine metabolism, catalyzes <strong>S\u2011adenosylmethionine (SAM)<\/strong> generation<\/li>\n\n\n\n<li><strong>MTAP Deletion<\/strong>: Common in <strong>15\u201120%<\/strong> of solid tumors (lung, pancreas, bladder, glioma)<\/li>\n\n\n\n<li><strong>Synthetic Lethality<\/strong>: <strong>MTAP\u2011deleted tumor cells<\/strong> are highly dependent on MAT2A for SAM production<\/li>\n<\/ul>\n\n\n\n<p><strong>Therapeutic Effect<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GH31 inhibition<\/strong>: Triggers <strong>SAM depletion<\/strong>, causing epigenetic disorders and DNA damage repair dysfunction<\/li>\n\n\n\n<li><strong>Selective Killing<\/strong>: <strong>Only MTAP\u2011deleted tumor cells<\/strong> die; normal cells survive via MTAP\u2011mediated salvage pathway<\/li>\n\n\n\n<li><strong>Safety Window<\/strong>: <strong>Broad therapeutic index<\/strong> due to selective tumor cell vulnerability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>MTAP\u2011Deleted Tumor Prevalence<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global incidence<\/strong>: <strong>300,000\u2011400,000<\/strong> new cases annually across solid tumor types<\/li>\n\n\n\n<li><strong>China patients<\/strong>: <strong>120,000\u2011150,000<\/strong> eligible patients annually<\/li>\n\n\n\n<li><strong>Current standard<\/strong>: No approved MAT2A inhibitors; chemotherapy\/immunotherapy with <strong>limited efficacy<\/strong><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2027E<\/th><th>2029E<\/th><th>2031E<\/th><\/tr><\/thead><tbody><tr><td><strong>Diagnosed MTAP\u2011deleted patients (China)<\/strong><\/td><td>85,000<\/td><td>100,000<\/td><td>115,000<\/td><\/tr><tr><td><strong>GH31\u2011eligible population<\/strong><\/td><td>60,000<\/td><td>72,000<\/td><td>85,000<\/td><\/tr><tr><td><strong>Peak penetration<\/strong><\/td><td>12%<\/td><td>25%<\/td><td>35%<\/td><\/tr><tr><td><strong>Annual therapy cost (\u00a5)<\/strong><\/td><td>\u00a5180,000<\/td><td>\u00a5150,000 (post\u2011NRDL)<\/td><td>\u00a5120,000<\/td><\/tr><tr><td><strong>China market potential<\/strong><\/td><td>\u00a51.30\u202fbillion<\/td><td>\u00a52.70\u202fbillion<\/td><td><strong>\u00a53.57\u202fbillion<\/strong> (US$500M)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Global Opportunity<\/strong>: <strong>US$2\u20113\u202fbillion<\/strong> peak sales potential across US, EU, and Asia\u2011Pacific markets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-development-pathway\">Global Development Pathway<\/h2>\n\n\n\n<p><strong>US &amp; China Parallel Development<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA<\/strong>: Phase\u202fI trial initiation Q1\u202f2026 at <strong>3\u20115 US sites<\/strong><\/li>\n\n\n\n<li><strong>NMPA<\/strong>: Phase\u202fI trial initiation Q1\u202f2026 at <strong>3\u20114 Chinese sites<\/strong><\/li>\n\n\n\n<li><strong>Trial Design<\/strong>: Dose\u2011escalation in <strong>MTAP\u2011deleted solid tumor<\/strong> patients, primary endpoint: safety and MTD<\/li>\n<\/ul>\n\n\n\n<p><strong>Advantages of Dual Approval<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Faster enrollment<\/strong>: Combined patient pool accelerates timeline by <strong>6\u20119 months<\/strong><\/li>\n\n\n\n<li><strong>Regulatory synergy<\/strong>: Data can support <strong>breakthrough therapy designation<\/strong> in both regions<\/li>\n\n\n\n<li><strong>Global filing<\/strong>: Phase\u202fII plans include <strong>global multi\u2011center trial<\/strong> for registration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Target<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>GH31<\/strong><\/td><td><strong>Genhouse Bio<\/strong><\/td><td><strong>MAT2A<\/strong><\/td><td><strong>Synthetic lethality (MTAP\u2011deleted)<\/strong><\/td><td><strong>Phase\u202f1<\/strong><\/td><td><strong>First\u2011in\u2011class<\/strong><\/td><\/tr><tr><td><strong>TNG908<\/strong><\/td><td>Tango Therapeutics<\/td><td>MAT2A<\/td><td>Synthetic lethality<\/td><td>Phase\u202fI\/II (US)<\/td><td>Clinical stage, no China presence<\/td><\/tr><tr><td><strong>AG\u2011270<\/strong><\/td><td>Agios Pharmaceuticals<\/td><td>MAT2A<\/td><td>Synthetic lethality<\/td><td>Phase\u202fI (discontinued)<\/td><td>Terminated due to toxicity<\/td><\/tr><tr><td><strong>IDE397<\/strong><\/td><td>Ideaya Biosciences<\/td><td>MAT2A<\/td><td>Synthetic lethality<\/td><td>Phase\u202fI (US)<\/td><td>Preliminary data, early stage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Global Race<\/strong>: Genhouse Bio is <strong>first to enter clinic<\/strong> with MAT2A inhibitor in China; <strong>TNG908<\/strong> is primary US competitor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-outlook\">Financial &amp; Strategic Outlook<\/h2>\n\n\n\n<p><strong>Investment<\/strong>: Viva Biotech\u2019s incubation model provides <strong>\u00a5150\u2011200\u202fmillion<\/strong> initial funding for GH31 development through Phase\u202fII.<\/p>\n\n\n\n<p><strong>Partnership Strategy<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Out\u2011licensing discussions<\/strong> underway for <strong>ex\u2011China rights<\/strong> (US\/EU\/Japan)<\/li>\n\n\n\n<li><strong>Target deal value<\/strong>: <strong>$500\u2011800\u202fmillion<\/strong> upfront + tiered royalties<\/li>\n<\/ul>\n\n\n\n<p><strong>IPO Pathway<\/strong>: Genhouse Bio targeting <strong>Hong Kong IPO<\/strong> in 2027, backed by Viva Biotech\u2019s track record of <strong>6 successful biotech listings<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding GH31&#8217;s clinical development, market potential, and competitive positioning. Actual results may differ materially due to clinical outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4529,1352],"class_list":["post-53055","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-genhouse-bio","tag-viva-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genhouse Bio&#039;s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China&#039;s National Medical Products Administration (NMPA) approved the clinical trial application for GH31, a Category\u202f1 MAT2A inhibitor, just 10 days after FDA approval. GH31 targets MTAP\u2011deleted tumors through a synthetic lethality mechanism, representing a first\u2011in\u2011class opportunity in solid tumor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53055\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genhouse Bio&#039;s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals\" \/>\n<meta property=\"og:description\" content=\"Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China&#039;s National Medical Products Administration (NMPA) approved the clinical trial application for GH31, a Category\u202f1 MAT2A inhibitor, just 10 days after FDA approval. GH31 targets MTAP\u2011deleted tumors through a synthetic lethality mechanism, representing a first\u2011in\u2011class opportunity in solid tumor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53055\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T05:56:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genhouse Bio&#8217;s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals\",\"datePublished\":\"2026-01-06T05:56:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055\"},\"wordCount\":548,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Genhouse Bio\",\"VIVA Biotech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53055#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53055\",\"name\":\"Genhouse Bio's MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604.webp\",\"datePublished\":\"2026-01-06T05:56:36+00:00\",\"description\":\"Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China's National Medical Products Administration (NMPA) approved the clinical trial application for GH31, a Category\u202f1 MAT2A inhibitor, just 10 days after FDA approval. GH31 targets MTAP\u2011deleted tumors through a synthetic lethality mechanism, representing a first\u2011in\u2011class opportunity in solid tumor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53055\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604.webp\",\"width\":1080,\"height\":608,\"caption\":\"Genhouse Bio's MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53055#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genhouse Bio&#8217;s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genhouse Bio's MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals - Insight, China&#039;s Pharmaceutical Industry","description":"Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China's National Medical Products Administration (NMPA) approved the clinical trial application for GH31, a Category\u202f1 MAT2A inhibitor, just 10 days after FDA approval. GH31 targets MTAP\u2011deleted tumors through a synthetic lethality mechanism, representing a first\u2011in\u2011class opportunity in solid tumor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53055","og_locale":"en_US","og_type":"article","og_title":"Genhouse Bio's MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals","og_description":"Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China's National Medical Products Administration (NMPA) approved the clinical trial application for GH31, a Category\u202f1 MAT2A inhibitor, just 10 days after FDA approval. GH31 targets MTAP\u2011deleted tumors through a synthetic lethality mechanism, representing a first\u2011in\u2011class opportunity in solid tumor therapy.","og_url":"https:\/\/flcube.com\/?p=53055","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-06T05:56:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53055#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53055"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genhouse Bio&#8217;s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals","datePublished":"2026-01-06T05:56:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53055"},"wordCount":548,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53055#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604.webp","keywords":["Clinical trial approval \/ initiation","Genhouse Bio","VIVA Biotech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53055#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53055","url":"https:\/\/flcube.com\/?p=53055","name":"Genhouse Bio's MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53055#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53055#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604.webp","datePublished":"2026-01-06T05:56:36+00:00","description":"Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China's National Medical Products Administration (NMPA) approved the clinical trial application for GH31, a Category\u202f1 MAT2A inhibitor, just 10 days after FDA approval. GH31 targets MTAP\u2011deleted tumors through a synthetic lethality mechanism, representing a first\u2011in\u2011class opportunity in solid tumor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53055#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53055"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53055#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604.webp","width":1080,"height":608,"caption":"Genhouse Bio's MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53055#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genhouse Bio&#8217;s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53055"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53055\/revisions"}],"predecessor-version":[{"id":53058,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53055\/revisions\/53058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53057"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}